Indeed, reduced IFN-γ production has been observed in a variety of human malignancies, including melanoma, gastric cancer, lung cancer, glioblastoma, nasopharyngeal carcinoma, colorectal cancer, and head and neck cancer (72). This evidence concerns the gene IFNG and gastric cancer.